title: Profile of prostanoid release following antigen challenge in vivo in the skin of man.
abstract: We have previously characterized the kinetics of prostaglandin D2 (PGD2) production at cutaneous sites of allergic inflammation employing a blister-chamber model. In this study, a more complete profile of prostaglandins released in vivo was obtained. PGD2 release, as measured by radioimmunoassay and by combined gas chromatography-mass spectrometry, was evident within 1 h after antigen challenge with maximal levels occurring 3-4 h post-challenge. The 11-ketoreductase metabolite of PGD2, 9 alpha, 11 beta-prostaglandin F2 was present in blister fluid from three of six patients at the time of maximal levels of PGD2. The stable non-enzymatic hydrolysis product of prostacyclin, 6-keto-prostaglandin F1 alpha, was significantly elevated in blister fluid from five of six patients following antigen challenge. In these subjects, the levels of 6 kappa-PGF1 alpha were highest in samples obtained 1 and 2 h after antigen challenge and remained significantly elevated until 5 h post-challenge. Levels of prostaglandin E2, prostaglandin F2 alpha and thromboxane B2 did not vary significantly. These studies suggest that following antigen challenge two fatty-acid cyclo-oxygenase products of arachidonic acid are released, PGD2 and prostacyclin. The 11-ketoreductase metabolism of PGD2 to 9 alpha, 11 beta-PGF2 could represent a mechanism by which the biological effects of PGD2 are prolonged in cutaneous tissue. The presence of 6 kappa-PGF1 alpha in the blister fluid suggests that significant prostacyclin release occurs as the result of antigen challenge and could represent a mechanism by which the prolonged microvascular response in cutaneous tissue may occur.
authors.affiliation: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
authors.forename: W A
authors.initials: WA
authors.lastname: Massey
authors.forename: W C
authors.initials: WC
authors.lastname: Hubbard
authors.forename: M C
authors.initials: MC
authors.lastname: Liu
authors.forename: A
authors.initials: A
authors.lastname: Kagey-Sobotka
authors.forename: P
authors.initials: P
authors.lastname: Cooper
authors.forename: L M
authors.initials: LM
authors.lastname: Lichtenstein
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D000328:Adult; D000941:Antigens / Q000276:immunology*; D001768:Blister / Q000378:metabolism; D015237:Dinoprost / Q000096:biosynthesis; D011464:Epoprostenol / Q000096:biosynthesis / Q000378:metabolism; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D011058:Pollen / Q000276:immunology*; D015230:Prostaglandin D2 / Q000096:biosynthesis; D011453:Prostaglandins / Q000096:biosynthesis*; D011863:Radioimmunoassay; D012867:Skin / Q000276:immunology* / Q000378:metabolism; D012882:Skin Tests / Q000379:methods; D013997:Time Factors
chemical_list: D000941:Antigens; D011453:Prostaglandins; D015121:6-Ketoprostaglandin F1 alpha; D015237:Dinoprost; D011464:Epoprostenol; D015230:Prostaglandin D2